BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shijiazhuang Yiling Pharmaceutical Co. Ltd readouts · AssetMe
 mo
X-WR-CALDESC:Upcoming readouts of studies Shijiazhuang Yiling Pharmaceutica
 l Co. Ltd's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05876832-2879@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:XY0206: Phase 3 readout est. (NCT05876832)
DESCRIPTION:XY0206\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study of X
 Y0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory 
 AML With FLT3-ITD-Mutation (ALIVE)\nEstimated primary completion: 1 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/xy0206#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05876832
URL:https://assetmemo.bio/drug/xy0206#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
